Free Trial
→ Where to Put $100 Before Trump's New Tech Law Rolls Out (From Brownstone Research) (Ad)tc pixel
NYSE:PEN

Penumbra Q1 2026 Earnings Report

Penumbra logo
$318.63 +0.31 (+0.10%)
Closing price 06/12/2026 03:59 PM Eastern
Extended Trading
$318.83 +0.20 (+0.06%)
As of 06/12/2026 05:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Penumbra EPS Results

Actual EPS
$0.82
Consensus EPS
$1.06
Beat/Miss
Missed by -$0.24
One Year Ago EPS
$0.83

Penumbra Revenue Results

Actual Revenue
$374.76 million
Expected Revenue
$370.47 million
Beat/Miss
Beat by +$4.29 million
YoY Revenue Growth
+15.60%

Penumbra Announcement Details

Quarter
Q1 2026
Date
5/6/2026
Time
Before Market Opens
Conference Call Date
Wednesday, May 6, 2026
Conference Call Time
4:00PM ET

Upcoming Earnings

Penumbra's Q2 2026 earnings is estimated for Tuesday, August 4, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, July 28, 2026 at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Penumbra's Q1 2026 Press ReleasePress Release
(8-K)
Penumbra's Q1 2026 Quarterly reportQuarterly report
(10-Q)

Penumbra Earnings Headlines

Penumbra Gets FDA Clearance for Technology for Treating Strokes
June 13 at 8:55 PM  |  marketwatch.comhttps://www.marketwatch.com/story/penumbra-gets-fda-clearance-for-technology-for-treating-strokes-c5f75d5d
Penumbra, Inc.: Penumbra's THUNDERBOLT Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology to Stroke
June 13 at 10:54 AM  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-06/68750720-penumbra-inc-penumbra-s-thunderbolt-receives-fda-clearance-bringing-computer-assisted-vacuum-thrombectomy-technology-to-stroke-008.htm
Read now. Do not delete. You’ve been warned.
Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.tc pixel
June 14 at 1:00 AM  |  Porter & Company (Ad)
Penumbra's THUNDERBOLT Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology to Stroke
June 11 at 4:05 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/penumbras-thunderbolt-receives-fda-clearance---bringing-computer-assisted-vacuum-thrombectomy-technology-to-stroke-302798514.html
Penumbra, Inc. (NYSE:PEN) Receives Average Recommendation of "Hold" from Analysts
June 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30822056
Here’s What Supports Penumbra’s (PEN) Revenue Growth and Margin Expansion
June 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/supports-penumbra-pen-revenue-growth-131412564.html
See More Penumbra Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Penumbra? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Penumbra and other key companies, straight to your email.

About Penumbra

Penumbra (NYSE:PEN) is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases. The company also offers embolization coil systems and flow-diversion devices for the treatment of cerebral aneurysms and vascular lesions. In its peripheral vascular line, Penumbra markets aspiration thrombectomy systems and small-vessel clot retrieval tools designed for limb salvage and treatment of pulmonary embolism.

Founded in 2004 by engineer Arani Bose, Penumbra launched its first commercial thrombectomy product in 2007 and has since expanded into new geographies and indications. The company maintains its headquarters in Alameda, California, with additional operations in Europe and Asia Pacific. Over the years, Penumbra has invested in R&D facilities and regulatory approvals to support product launches across more than 100 countries.

Under the leadership of President and Chief Executive Officer Adam Elsesser, Penumbra continues to advance its pipeline of next-generation devices, focusing on catheter design, clot visualization and real-time feedback technologies. The company collaborates with academic institutions and clinical specialists to refine procedural techniques and drive evidence generation in stroke and vascular care.

View Penumbra Profile
Earnings Tools